Nick D Tsihlis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2590856/publications.pdf

Version: 2024-02-01

34	728	687363 13	526287 27
papers	citations	h-index	g-index

36	36	36	1016
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Peptide Amphiphile Supramolecular Nanofibers Designed to Target Abdominal Aortic Aneurysms. ACS Nano, 2022, 16, 7309-7322.	14.6	6
2	Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models. Pediatric Research, 2021, 89, 1641-1649.	2.3	5
3	Coating small-diameter ePTFE vascular grafts with tunable poly(diol-co-citrate-co-ascorbate) elastomers to reduce neointimal hyperplasia. Biomaterials Science, 2021, 9, 5160-5174.	5.4	7
4	Evaluation of a Targeted Drugâ€Eluting Intravascular Nanotherapy to Prevent Neointimal Hyperplasia in an Atherosclerotic Rat Model. Advanced NanoBiomed Research, 2021, 1, 2000093.	3.6	0
5	Intravenous Delivery of Lungâ€Targeted Nanofibers for Pulmonary Hypertension in Mice. Advanced Healthcare Materials, 2021, 10, e2100302.	7.6	10
6	Selfâ€Assembled Peptide Amphiphile Nanofibers for Controlled Therapeutic Delivery to the Atherosclerotic Niche. Advanced Therapeutics, 2021, 4, 2100103.	3.2	6
7	Development of novel nanofibers targeted to smoke-injured lungs. Biomaterials, 2021, 274, 120862.	11.4	5
8	Emerging Therapies for Prehospital Control of Hemorrhage. Journal of Surgical Research, 2020, 248, 182-190.	1.6	11
9	Pharmacokinetics and biodistribution of a collagenâ€targeted peptide amphiphile for cardiovascular applications. Pharmacology Research and Perspectives, 2020, 8, e00672.	2.4	7
10	A comparative study of a preclinical survival model of smoke inhalation injury in mice and rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L471-L480.	2.9	6
11	Development of Optimized Tissue-Factor-Targeted Peptide Amphiphile Nanofibers to Slow Noncompressible Torso Hemorrhage. ACS Nano, 2020, 14, 6649-6662.	14.6	28
12	Development of Poly(1,8-octanediol-co-citrate-co-ascorbate) Elastomers with Enhanced Ascorbate Performance for Use as a Graft Coating to Prevent Neointimal Hyperplasia. ACS Applied Bio Materials, 2020, 3, 2150-2159.	4.6	13
13	Development of Fractalkine-Targeted Nanofibers that Localize to Sites of Arterial Injury. Nanomaterials, 2020, 10, 420.	4.1	7
14	Emerging therapies for smoke inhalation injury: a review. Journal of Translational Medicine, 2020, 18, 141.	4.4	7
15	Peptide Amphiphile Supramolecular Nanostructures as a Targeted Therapy for Atherosclerosis. Macromolecular Bioscience, 2019, 19, e1900066.	4.1	29
16	Atheroma Nicheâ€Responsive Nanocarriers for Immunotherapeutic Delivery. Advanced Healthcare Materials, 2019, 8, e1801545.	7.6	26
17	Systemic Delivery of a Novel Fractalkine Binding Peptide Amphiphile Nanofiber to Target Injured Vasculature. Journal of the American College of Surgeons, 2018, 227, S296-S297.	0.5	0
18	Nitric oxide differentially affects proteasome activator 28 after arterial injury in type 1 and type 2 diabetic rats. Journal of Surgical Research, 2016, 202, 413-421.	1.6	2

#	Article	IF	Citations
19	Tissue-Factor Targeted Peptide Amphiphile Nanofibers as an Injectable Therapy To Control Hemorrhage. ACS Nano, 2016, 10, 899-909.	14.6	72
20	Nitric oxide affects UbcH10 levels differently in type 1 and type 2 diabetic rats. Journal of Surgical Research, 2015, 196, 180-189.	1.6	1
21	Nitric oxide is less effective at inhibiting neointimal hyperplasia in spontaneously hypertensive rats. Nitric Oxide - Biology and Chemistry, 2013, 35, 165-174.	2.7	4
22	Nitric oxide delivery via a permeable balloon catheter inhibits neointimal growth after arterial injury. Journal of Surgical Research, 2013, 180, 35-42.	1.6	17
23	Nitric oxide may inhibit neointimal hyperplasia by decreasing isopeptidase T levels and activity in the vasculature. Journal of Vascular Surgery, 2013, 58, 179-186.	1.1	3
24	Nitric oxide decreases activity and levels of the 11S proteasome activator PA28 in the vasculature. Nitric Oxide - Biology and Chemistry, 2012, 27, 50-58.	2.7	15
25	Nitric Oxide Increases Lysine 48-Linked Ubiquitination Following Arterial Injury. Journal of Surgical Research, 2011, 170, e169-e177.	1.6	6
26	Nitric Oxide Inhibits Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia by Increasing the Ubiquitination and Degradation of UbcH10. Cell Biochemistry and Biophysics, 2011, 60, 89-97.	1.8	67
27	Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. Journal of Vascular Surgery, 2010, 51, 1248-1259.	1.1	52
28	Basic Science Review: Nitric Oxideâ€"Releasing Prosthetic Materials. Vascular and Endovascular Surgery, 2009, 43, 121-131.	0.7	39
29	Nitric oxide and nanotechnology: A novel approach to inhibit neointimal hyperplasia. Journal of Vascular Surgery, 2008, 47, 173-182.	1.1	122
30	Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H2388-H2398.	3.2	31
31	The role of nitric oxide in the pathophysiology of intimal hyperplasia. Journal of Vascular Surgery, 2007, 45, A64-A73.	1.1	89
32	Antiâ€proliferative properties of IPA/NO: a novel use of an HNOâ€eluting compound. FASEB Journal, 2007, 21, A1129.	0.5	0
33	The Saccharomyces cerevisiae RNA polymerase III recruitment factor subunits Brf1 and Bdp1 impose a strict sequence preference for the downstream half of the TATA box. Nucleic Acids Research, 2006, 34, 5585-5593.	14.5	4
34	Surface salt bridges modulate the DNA site size of bacterial histone-like HU proteins. Biochemical Journal, 2005, 390, 49-55.	3.7	25